FDA approves rituximab plus chemotherapy for pediatric cancer indications
Oncology / Hematology (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 3, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Janssen Seeks Approval of IMBRUVICA ®(ibrutinib) in a Fixed-Duration Regimen for Patients with Untreated Chronic Lymphocytic Leukaemia (CLL)
BEERSE, BELGIUM, 30 November 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Type II variation application to the European Medicines Agency (EMA) seeking approval of a new treatment option for IMBRUVICA® (ibrutinib) as a fixed-duration combination with venetoclax (I+V) for adult patients with previously untreated chronic lymphocytic leukaemia (CLL)."Ibrutinib was the first approved Bruton’s tyrosine kinase inhibitor and over the past seven years has become a key treatment for CLL and some other B-cell malignancies, treating more than 250,000 patients globally,â€...
Source: Johnson and Johnson - November 30, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Low-Dose Rituximab May Keep RA Activity Low in Responders Low-Dose Rituximab May Keep RA Activity Low in Responders
Rituximab doses as low as 200 mg were effective in treating rheumatoid arthritis, an extension study of a small trial in the Netherlands found.Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - November 19, 2021 Category: Rheumatology Tags: Rheumatology News Source Type: news
Rituximab, Cyclophosphamide Similar for Inducing EGPA Remission Rituximab, Cyclophosphamide Similar for Inducing EGPA Remission
A phase 3 trial has found that rituximab is not superior to cyclophosphamide to induce remission in eosinophilic granulomatosis with polyangiitis.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - November 17, 2021 Category: Drugs & Pharmacology Tags: Rheumatology News Source Type: news
Adding Rituximab to Belimumab Offers No Help for Lupus Adding Rituximab to Belimumab Offers No Help for Lupus
The combination of rituximab and belimumab was associated with a longer duration of response, but there was no benefit of belimumab alone for disease control at 1 year.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - November 15, 2021 Category: Dermatology Tags: Rheumatology News Source Type: news
Ultra-Low Dose of Rituximab Safely Eases Rheumatoid Arthritis Over Long Term: Study
Title: Ultra-Low Dose of Rituximab Safely Eases Rheumatoid Arthritis Over Long Term: StudyCategory: Health NewsCreated: 11/9/2021 12:00:00 AMLast Editorial Review: 11/10/2021 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - November 10, 2021 Category: Rheumatology Source Type: news
Rituximab Improves Systemic Sclerosis Skin, Lung Symptoms Rituximab Improves Systemic Sclerosis Skin, Lung Symptoms
Patients who took rituximab in the DESIRES trial had better skin scores and lung function at 6 months than did patients who received placebo.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - November 8, 2021 Category: Dermatology Tags: Rheumatology News Source Type: news
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Rituximab More Effective Than Other MS Treatments? Rituximab More Effective Than Other MS Treatments?
Rituximab reduced relapses and MRI activity more effectively than dimethyl fumarate, natalizumab, and injectable therapies in a recent study. Disability did not differ between treatments, however.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 15, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
New four-year data show Roche's ENSPRYNG significantly reduces debilitating relapses in people with neuromyelitis optica spectrum disorder
Basel, 14 October 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new longer-term efficacy and safety data for ENSPRYNG® (satralizumab). The data show ENSPRYNG has a favourable benefit:risk profile and is effective in reducing relapses over four years of treatment in people with anti-aquaporin-4 antibody (AQP 4-IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD), a rare debilitating disease that affects the central nervous system. Efficacy and safety results from the open-label extension (OLE) periods of the SAkuraStar and SAkuraSky studies, in addition to the design of SAkuraBONSAI, a new s tudy ...
Source: Roche Media News - October 14, 2021 Category: Pharmaceuticals Source Type: news
New four-year data show Roche's ENSPRYNG significantly reduces debilitating relapses in people with neuromyelitis optica spectrum disorder
Basel, 14 October 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new longer-term efficacy and safety data for ENSPRYNG® (satralizumab). The data show ENSPRYNG has a favourable benefit:risk profile and is effective in reducing relapses over four years of treatment in people with anti-aquaporin-4 antibody (AQP 4-IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD), a rare debilitating disease that affects the central nervous system. Efficacy and safety results from the open-label extension (OLE) periods of the SAkuraStar and SAkuraSky studies, in addition to the design of SAkuraBONSAI, a new s tudy ...
Source: Roche Investor Update - October 14, 2021 Category: Pharmaceuticals Source Type: news
COVID-19 Vax in MS: Lower Response on Certain Medications COVID-19 Vax in MS: Lower Response on Certain Medications
New data on COVID vaccination in MS patients has shown a reduced humoral response in patients treated with certain medications -- including ocrelizumab, rituximab, and fingolimod -- but not others.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - October 14, 2021 Category: Infectious Diseases Tags: Neurology & Neurosurgery News Source Type: news
Clinical commissioning policy: Rituximab
This clinical commissioning policy sets out the criteria for Rituximab as a treatment option through routine commissioning for nodal/paranodal antibody positive inflammatory/autoimmune neuropathy in adults and postpubescent children. (Source: NHS Networks)
Source: NHS Networks - October 6, 2021 Category: UK Health Source Type: news
Roche to present new data on OCREVUS in multiple sclerosis and ENSPRYNG in neuromyelitis optica spectrum disorder at ECTRIMS 2021
Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS ® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) from 13 - 15 October 2021. These data include 38 abstracts highlighting new longer-term efficacy and safety for both OCREVUS and ENSPRYNG, as well as our ongoing efforts to evaluate the impact of the COVID-19 pandemic for people living with MS. Additional data will show how a deeper scientific understanding of MS and NMOSD in diverse patient populations could ...
Source: Roche Investor Update - October 5, 2021 Category: Pharmaceuticals Source Type: news
Roche to present new data on OCREVUS in multiple sclerosis and ENSPRYNG in neuromyelitis optica spectrum disorder at ECTRIMS 2021
Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS ® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) from 13 - 15 October 2021. These data include 38 abstracts highlighting new longer-term efficacy and safety for both OCREVUS and ENSPRYNG, as well as our ongoing efforts to evaluate the impact of the COVID-19 pandemic for people living with MS. Additional data will show how a deeper scientific understanding of MS and NMOSD in diverse patient populations could ...
Source: Roche Media News - October 5, 2021 Category: Pharmaceuticals Source Type: news
